A global consensus statement backs active surveillance as a management strategy for patients with low-grade non-muscle-invasive bladder cancer (LG-NMIBC). The approach aims to reduce overtreatment and the long-term burden of repeated interventions while maintaining careful monitoring. The report frames the guidance as a shift from automatic escalation to frequent procedures, using surveillance to tailor treatment intensity based on risk and disease behavior over time. For uro-oncology stakeholders, the consensus may affect how clinicians counsel patients and how trial endpoints are designed going forward. The key industry impact is operational: more patients may remain on surveillance pathways, changing healthcare utilization patterns and potentially shifting demand for biomarker-driven monitoring tools.